Michael Mark - Concepedia

Author

Michael Mark

Kantonsspital Graubünden

Also Known As

M. Mark, M.T. Mark, Mark, Michael Thomas, Michael Thomas Mark, Michael Mark, Michael T. Mark, Michael Thomas Mark

Publications

1.2K

Citations

H-Index

Concepts

All Affiliations

Kantonsspital Graubünden Swiss Group For Clinical Cancer Research Kantonsspital Winterthur Kantonsspital St. Gallen University Hospital of Basel

About

Michael Mark is an author at Kantonsspital Graubünden specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	13	14	414
2	Health Sciences	3	3	106
3	Immunology	3	3	69
4	Biochemistry	1	1	13
5	Neuroscience	1	1	36

Michael Mark

Publications

976

Citations

H-Index

Page 1

	Year	Citations
SAKK 16/14: Durvalumab in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non–Small-Cell Lung Cancer—A Multicenter Single-Arm Phase II Trial Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet, Journal of Clinical Oncology	2021	336
Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs) Sabine Schmid, Oliver Gautschi, Sacha I. Rothschild, Journal of Thoracic Oncology De Novo EgfrMedicinePathologyCancer TreatmentCancer Genetics	2016	72
The Influence of Two Different Hydroxyethyl Starch Solutions (6% HES 130/0.4 and 200/0.5) on Blood Viscosity Thomas A. Neff, Lukas Fischler, Michael Mark, Anesthesia & Analgesia	2005	50
A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial Solange Peters, Sarah Danson, Baktiar Hasan, Journal of Thoracic Oncology Advanced NsclcOncologySplendour TrialClinical TrialsImmune Checkpoint Inhibitor	2020	49
Cross-sectional study of self-reported physical activity, eating habits and use of complementary medicine in breast cancer survivors Arnoud J. Templeton, Beat Thürlimann, Michael R. Baumann, BMC Cancer	2013	43
SAKK 16/14: Anti-PD-L1 antibody durvalumab in addition to neoadjuvant chemotherapy in patients with stage IIIA(N2) non-small cell lung cancer (NSCLC)—A multicenter single-arm phase II trial. Sacha I. Rothschild, Alfred Zippelius, E.I. Eboulet, Journal of Clinical Oncology Pd-l1 StatusSurgical OncologySakk 16/14MedicineAnti-pd-l1 Antibody Durvalumab	2020	39
Impact of Early Prophylactic Cranial Irradiation With Hippocampal Avoidance on Neurocognitive Function in Patients With Limited Disease Small Cell Lung Cancer. A Multicenter Phase 2 Trial (SAKK 15/12) Hansjörg Vees, Francesca Caparrotti, E.I. Eboulet, International Journal of Radiation OncologyBiologyPhysics Neuro-oncologyRadiation MedicineRadiation TherapyMedicineNeurocognitive Function	2020	36
Commercial taxane formulations induce stomatocytosis and increase blood viscosity Michael Mark, Roland B. Walter, D.O. Meredith, British Journal of Pharmacology	2001	33
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16) Yannis Metaxas, Martin Früh, E.I. Eboulet, Annals of Oncology Surgical OncologyMalignant Pleural MesotheliomaMedicinePathologyPleural Disease	2020	32
Phase I trial of the oral smoothened inhibitor sonidegib in combination with paclitaxel in patients with advanced solid tumors Anastasios Stathis, Dagmar Hess, Roger von Moos, Investigational New Drugs OncologyMedicineAdvanced Solid TumorsPharmacotherapyAnti-cancer Agent	2017	31

Page 1